368 related articles for article (PubMed ID: 12011283)
1. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit.
Silber E; Semra YK; Gregson NA; Sharief MK
Neurology; 2002 May; 58(9):1372-81. PubMed ID: 12011283
[TBL] [Abstract][Full Text] [Related]
2. Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
Amor S; van der Star BJ; Bosca I; Raffel J; Gnanapavan S; Watchorn J; Kuhle J; Giovannoni G; Baker D; Malaspina A; Puentes F
Mult Scler; 2014 Sep; 20(10):1355-62. PubMed ID: 24515731
[TBL] [Abstract][Full Text] [Related]
3. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis.
Ehling R; Lutterotti A; Wanschitz J; Khalil M; Gneiss C; Deisenhammer F; Reindl M; Berger T
Mult Scler; 2004 Dec; 10(6):601-6. PubMed ID: 15584481
[TBL] [Abstract][Full Text] [Related]
4. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy.
Eikelenboom MJ; Petzold A; Lazeron RH; Silber E; Sharief M; Thompson EJ; Barkhof F; Giovannoni G; Polman CH; Uitdehaag BM
Neurology; 2003 Jan; 60(2):219-23. PubMed ID: 12552034
[TBL] [Abstract][Full Text] [Related]
5. Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association.
Mantegazza R; Cristaldini P; Bernasconi P; Baggi F; Pedotti R; Piccini I; Mascoli N; La Mantia L; Antozzi C; Simoncini O; Cornelio F; Milanese C
Int Immunol; 2004 Apr; 16(4):559-65. PubMed ID: 15039386
[TBL] [Abstract][Full Text] [Related]
6. Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index.
de Bock L; Fraussen J; Villar LM; Álvarez-Cermeño JC; Van Wijmeersch B; van Pesch V; Stinissen P; Somers V
Eur J Neurol; 2016 Apr; 23(4):722-8. PubMed ID: 26706657
[TBL] [Abstract][Full Text] [Related]
7. [Neurofilament protein light in multiple sclerosis].
Zhang Y; Li X; Qiao J
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2745-9. PubMed ID: 18167263
[TBL] [Abstract][Full Text] [Related]
8. High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients.
Hecker M; Fitzner B; Wendt M; Lorenz P; Flechtner K; Steinbeck F; Schröder I; Thiesen HJ; Zettl UK
Mol Cell Proteomics; 2016 Apr; 15(4):1360-80. PubMed ID: 26831522
[TBL] [Abstract][Full Text] [Related]
9. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
[TBL] [Abstract][Full Text] [Related]
10. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy.
Elovaara I; Ukkonen M; Leppäkynnäs M; Lehtimäki T; Luomala M; Peltola J; Dastidar P
Arch Neurol; 2000 Apr; 57(4):546-51. PubMed ID: 10768630
[TBL] [Abstract][Full Text] [Related]
11. Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis.
Verbeek MM; Notting EA; Faas B; Claessens-Linskens R; Jongen PJ
Acta Neurol Scand; 2010 May; 121(5):309-14. PubMed ID: 19925532
[TBL] [Abstract][Full Text] [Related]
12. Serum and cerebrospinal fluid heavy neurofilaments and antibodies against them in early multiple sclerosis.
Fialová L; Bartos A; Švarcová J; Zimova D; Kotoucova J
J Neuroimmunol; 2013 Jun; 259(1-2):81-7. PubMed ID: 23632043
[TBL] [Abstract][Full Text] [Related]
13. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
[TBL] [Abstract][Full Text] [Related]
15. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.
Brettschneider J; Jaskowski TD; Tumani H; Abdul S; Husebye D; Seraj H; Hill HR; Fire E; Spector L; Yarden J; Dotan N; Rose JW
J Neuroimmunol; 2009 Dec; 217(1-2):95-101. PubMed ID: 19879655
[TBL] [Abstract][Full Text] [Related]
16. Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis.
Szmyrka-Kaczmarek M; Pokryszko-Dragan A; Pawlik B; Gruszka E; Korman L; Podemski R; Wiland P; Szechinski J
Lupus; 2012 Apr; 21(4):412-20. PubMed ID: 22074845
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies.
Castellazzi M; Contini C; Tamborino C; Fasolo F; Roversi G; Seraceni S; Rizzo R; Baldi E; Tola MR; Bellini T; Granieri E; Fainardi E
J Neuroinflammation; 2014 Nov; 11():188. PubMed ID: 25391491
[TBL] [Abstract][Full Text] [Related]
18. Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients.
Gresle MM; Liu Y; Dagley LF; Haartsen J; Pearson F; Purcell AW; Laverick L; Petzold A; Lucas RM; Van der Walt A; Prime H; Morris DR; Taylor BV; ; Shaw G; Butzkueven H
J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1209-13. PubMed ID: 24639436
[TBL] [Abstract][Full Text] [Related]
19. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry.
Teunissen CE; Koel-Simmelink MJ; Pham TV; Knol JC; Khalil M; Trentini A; Killestein J; Nielsen J; Vrenken H; Popescu V; Dijkstra CD; Jimenez CR
Mult Scler; 2011 Jul; 17(7):838-50. PubMed ID: 21505015
[TBL] [Abstract][Full Text] [Related]
20. Correlation Between Anti-Myelin Proteolipid Protein (PLP) Antibodies and Disease Severity in Multiple Sclerosis Patients With PLP Response-Permissive HLA Types.
Greer JM; Trifilieff E; Pender MP
Front Immunol; 2020; 11():1891. PubMed ID: 32973782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
